Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 9,800 shares, a decline of 13.3% from the July 15th total of 11,300 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 16,900 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Lisata Therapeutics in a research report on Tuesday, August 13th.

Institutional Trading of Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. BML Capital Management LLC increased its stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 269,839 shares of the company’s stock after acquiring an additional 26,000 shares during the period. Lisata Therapeutics makes up 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 24th largest position. BML Capital Management LLC owned about 3.31% of Lisata Therapeutics worth $737,000 as of its most recent filing with the SEC. 8.94% of the stock is owned by institutional investors.

Lisata Therapeutics Stock Performance

Shares of LSTA opened at $2.85 on Friday. Lisata Therapeutics has a 1 year low of $1.95 and a 1 year high of $3.83. The company’s 50 day simple moving average is $3.35 and its 200 day simple moving average is $3.09. The company has a market capitalization of $23.67 million, a price-to-earnings ratio of -1.16 and a beta of 1.24.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.14. During the same period in the previous year, the business posted ($0.50) EPS. Equities analysts expect that Lisata Therapeutics will post -3.08 EPS for the current fiscal year.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.